mProX™ Human EML4 Stable Cell Line

Product Information

Target Protein

EML4

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

HeLa; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research

Related Diseases

Lymphoma and Lung Cancer. Among its related pathways are Signaling by ALK in cancer and "Cell Cycle, Mitotic"

Gene ID

27436

UniProt ID

Q9HC35

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The human EML4 gene encodes a protein known as echinoderm microtubule-associated protein-like 4. The splicing of this protein with anaplastic lymphoma kinase results in its involvement in malignancies. The ALK-EML4 fusion links the ALK gene to "echinoderm microtubule associated protein-like 4" (EML4), a gene involved in microtubule production and stabilization. A transforming fusion tyrosine kinase is produced by this fusion, and lung tumors have been found to express many isoforms of this enzyme. ALK and EML4 are oppositely orientated and situated on the short arm of chromosome 2, separated by a distance of 12 megabases (Mb) in sequence. Over nine distinct variations of the EML4-ALK fusion have been discovered thus far. The customized EML4 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat John

This EML4 cell line is the best choice for laboratories wishing to minimise troubleshooting time and maximise data and experimental volumes. Dec 25 2022

chat Verified Customer

chat Stephanie

The ideal EML4 cell line, often used in our laboratories. Jul 10 2022

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Phase separation of EML4-ALK variant 1 in human cancer cell lines.

GFP-EML4-ALK was transfected into HeLa cells, and after 24 hours, the GFP-EML4-ALK was visible through confocal microscopy. DAPI was used to label the nucleus (blue).

Ref: Qin, Zhen, et al. "Phase separation of EML4-ALK in firing downstream signaling and promoting lung tumorigenesis." Cell Discovery 7.1 (2021): 33.

Pubmed: 33976114

DOI: 10.1038/s41421-021-00270-5

Research Highlights

Molecular-targeted therapy has undergone a revolution since the identification of at least 15 distinct variants in lung cancers following the 2007 discovery of the fusion between EML4 (echinoderm microtubule associated protein-like 4) and ALK (anaplastic lymphoma kinase), or EML4-ALK, in lung adenocarcinomas. This discovery has significantly improved the prognosis for these patients.
Sabir, Sarah R., et al. "EML4-ALK variants: biological and molecular properties, and the implications for patients." Cancers 9.9 (2017): 118.
Pubmed: 28872581 DOI: 10.3390/cancers9090118

In non-small cell lung cancer (NSCLC), a fusion between the genes ALK (anaplastic lymphoma kinase) and EML4 (echinoderm microtubule-associated protein-like) was discovered in 2007. Since then, there has been significant advancement in the application of this knowledge for the benefit of patients.
Bayliss, Richard, et al. "Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs." Cellular and molecular life sciences 73 (2016): 1209-1224.
Pubmed: 26755435 DOI: 10.1007/s00018-015-2117-6